Westpac Banking Corp Takes $437,000 Position in Medpace Holdings, Inc. $MEDP

Westpac Banking Corp acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 826 shares of the company’s stock, valued at approximately $437,000.

A number of other hedge funds also recently added to or reduced their stakes in MEDP. California State Teachers Retirement System increased its position in Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after purchasing an additional 4,719 shares during the period. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Medpace in the 2nd quarter worth approximately $1,685,000. Cerity Partners LLC lifted its position in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after purchasing an additional 23,530 shares during the period. BlackRock Inc. bought a new position in shares of Medpace during the second quarter valued at approximately $1,323,047,000. Finally, Local Pensions Partnership Investment Ltd boosted its stake in shares of Medpace by 10.5% during the second quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company’s stock valued at $22,265,000 after purchasing an additional 4,000 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Up 1.3%

Shares of Medpace stock opened at $620.75 on Friday. The firm’s 50 day moving average price is $550.16 and its 200-day moving average price is $492.71. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market cap of $17.33 billion, a P/E ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. Medpace’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Truist Financial lifted their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Robert W. Baird lifted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $584.18.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 122,261 shares of company stock valued at $71,729,129. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.